Author： Lori Franco Weiner David Calarota Sandra Kelly Laurene Lisziewicz Julianna
Publisher： Springer Publishing Company
ISSN： 0344-4325
Source： Springer Seminars in Immunopathology, Vol.28, Iss.3, 2006-11, pp. : 231-238
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
This review highlights some of the most common cytokines currently being tested as adjuvants in HIV-1-DNA vaccine regimens. We discuss their use in both the prophylactic and therapeutic setting. Finally, we describe a novel dendritic cell-targeted vaccine candidate for HIV-1 treatment and prevention called DermaVir and explore the combination of the DermaVir technology with the cytokine adjuvants interleukin-7 and interleukin-15.
Related content
By Hamajima K. Sasaki S. Fukushima J. Kaneko T. Xin K-Q. Kudoh I. Okuda K.
Clinical Immunology, Vol. 88, Iss. 2, 1998-08 ,pp. :
Access to resources
Recommend
The Cytokine Network in HIV Infection
Current Molecular Medicine, Vol. 2, Iss. 8, 2002-12 ,pp. :
Mucosa-targeted DNA vaccination
Trends in Immunology, Vol. 22, Iss. 12, 2001-12 ,pp. :
DNA vaccines for HIV: challenges and opportunities
Springer Seminars in Immunopathology, Vol. 28, Iss. 3, 2006-11 ,pp. :